May 26, 2017 09:33 AM EDTUpdated 10:27 AM
News Briefing

Venn and Uni­ver­si­ty of Utah part­ner on im­muno-on­col­o­gy mol­e­cule; Bio­gen los­ing an­oth­er ex­ec

Emma Yasinski

→ Venn Ther­a­peu­tics plans to ad­vance a small mol­e­cule de­signed by Haitao (Mark) Ji at the Uni­ver­si­ty of Utah. The mol­e­cule is a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

New Flag­ship start­up aims to trail­blaze ‘AI sci­ence fac­to­ries’

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

Emer­gent sells once-trou­bled man­u­fac­tur­ing site to In­di­an CD­MO

#AAD25: What you need to know from Am­gen, Bris­tol My­ers, J&J and more

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times